Evan Feinberg, CEO of Genesis Therapeutics (Boris Feldman)

Genen­tech-part­nered Gen­e­sis Ther­a­peu­tics inks newest AI dis­cov­ery deal with Eli Lil­ly

A Stan­ford biotech rubbed el­bows with Genen­tech in 2020, reach­ing a deal with the big-name biotech just over 18 months ago. And now, the AI out­fit is in its sec­ond part­ner­ship with Big Phar­ma.

Gen­e­sis Ther­a­peu­tics se­cured a deal with big phar­ma Eli Lil­ly, the com­pa­ny an­nounced on Tues­day — to dis­cov­er ther­a­pies “across a range of ther­a­peu­tic ar­eas,” ac­cord­ing to a state­ment put out by the biotech.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.